Wednesday, July 8, 2026

Patent intelligence · US

US 9855226

d-methadone for the treatment of psychiatric symptoms

granted A61KA61K31/137A61K45/06A61K9/0019
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 11
Applicant portfolio 7
Patent details — US 9855226
Jurisdiction
US
Status
granted
Grant date
Jan 2, 2018
Expiration
Dec 28, 2037
Claims
20
CPC classes
A61K, A61K31/137, A61K45/06, A61K9/0019
View on Google Patents ↗

Quick answer

US 9855226 (d-methadone for the treatment of psychiatric symptoms) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Jan 2, 2018. Expires Dec 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/137, A61K45/06, A61K9/0019, A61P, A61P25/00

More from Relmada Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11607407

    Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use

    Relmada Therapeutics, Inc. · Expires Mar 16, 2043

    granted
  2. US 10624887

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol

    Relmada Therapeutics, Inc. · Expires Apr 16, 2040

    granted
  3. US 9468611

    d-Methadone for the treatment of psychiatric symptoms

    Relmada Therapeutics, Inc. · Expires Oct 13, 2036

    granted
  4. US 9364430

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol

    Relmada Therapeutics, Inc. · Expires Jun 9, 2036

    granted
  5. US 9125833

    Multimodal abuse resistant and extended release opioid formulations

    Relmada Therapeutics, Inc. · Expires Sep 3, 2035

    granted
  6. US 8329744

    Methods of preventing the serotonin syndrome and compositions for use thereof

    Relmada Therapeutics, Inc. · Expires Dec 6, 2032

    granted

Frequently asked questions

What is US patent 9855226?

US 9855226 (d-methadone for the treatment of psychiatric symptoms) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Jan 2, 2018. Expires Dec 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9855226?

Relmada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.

When does US 9855226 expire?

Our index shows an expiration date of Dec 28, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.